Lanxia Liu
Overview
Explore the profile of Lanxia Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bai X, Liu L, Qian J, Liu R, Du Z, Ni R, et al.
Anal Methods
. 2025 Feb;
17(9):2059-2066.
PMID: 39932254
Haloacetic acids (HAAs) are among the most common drinking water disinfection byproducts (DBPs) and are of widespread concern due to their potential carcinogenicity and reproductive health risks. However, data on...
2.
Deng B, Ma Y, Huang J, He R, Luo M, Mao L, et al.
Sci Adv
. 2024 Jun;
10(23):eado1550.
PMID: 38848358
The utilization of three-dimensional (3D) bioprinting technology to create a transplantable bioartificial liver emerges as a promising remedy for the scarcity of liver donors. This study outlines our strategy for...
3.
Lu L, Mao T, Xu R, Liu L, Qian J, Yang K, et al.
Int Arch Occup Environ Health
. 2023 Jul;
96(8):1123-1136.
PMID: 37400582
Objective: The current study aims to explore the effects of nine urine monohydroxy PAH metabolites (OHPAH) including 1-hydroxynaphthalene (1-OHNAP), 2-hydroxynaphthalene (2-OHNAP), 3-hydroxyfluorene (3-OHFLU), 9-hydroxyfluorene (9-OHFLU), 1-hydroxyphenanthrene (1-OHPHE), 2-hydroxyphenanthrene (2-OHPHE), 3-hydroxyphenanthrene...
4.
Ma B, Ma Y, Deng B, Xiao P, Huang P, Wang D, et al.
J Nanobiotechnology
. 2023 May;
21(1):171.
PMID: 37237292
Certain chemotherapeutics can induce tumor cells' immunogenic cell death (ICD), release tumor antigens, and thereby trigger personalized antitumor immune responses. Co-delivery of adjuvants using nanocarriers could amplify the ICD-induced tumor-specific...
5.
Chen P, Wang D, Wang Y, Zhang L, Wang Q, Liu L, et al.
Nano Lett
. 2022 May;
22(10):4058-4066.
PMID: 35522597
Nucleic-acid-based immune adjuvants have been extensively investigated for the design of cancer vaccines. However, nucleic acids often require the assistance of a carrier system to improve cellular uptake. Yet, such...
6.
Deng B, Ma B, Ma Y, Cao P, Leng X, Huang P, et al.
J Nanobiotechnology
. 2022 Mar;
20(1):140.
PMID: 35303868
Chemotherapeutics that can trigger immunogenic cell death (ICD) and release tumor-specific antigens are effective on treating a variety of cancers. The codelivery of chemotherapeutics with adjuvants is a promising strategy...
7.
Liu D, Deng B, Liu Z, Ma B, Leng X, Kong D, et al.
Nano Lett
. 2021 Apr;
21(9):3965-3973.
PMID: 33886338
Nanovaccines have emerged as promising agents for cancer immunotherapy. However, insufficient antitumor immunity caused by inefficient antigen/adjuvant loading and complicated preparation processes are the major obstacles that limit their clinical...
8.
Liu D, Liu J, Ma B, Deng B, Leng X, Kong D, et al.
Biomater Sci
. 2020 Oct;
9(1):84-92.
PMID: 33016303
Biomimetic nanoparticles have potential applications in many fields due to their favorable properties. Here, we developed a self-adjuvanting biomimetic anti-tumor nanovaccine, which was self-assembled with an amphiphilic conjugate synthesized with...
9.
Zhang J, Liu D, Liu J, Han Y, Xu H, Leng X, et al.
Biomater Sci
. 2020 Aug;
8(17):4757-4766.
PMID: 32840510
Combined blockades of CTLA-4 and PD-1 can yield better overall complementary clinical outcomes than individual blockades, but the response rates are still relatively low. To investigate the anti-tumor effects of...
10.
Liu X, Liu J, Liu D, Han Y, Xu H, Liu L, et al.
Biomater Sci
. 2019 Nov;
7(12):5516-5527.
PMID: 31670734
Exogenous antigens processed in the cytosol and subsequently cross-presented on major histocompatibility complex class I (MHC-I) molecules activate cytotoxic CD8 lymphocytes (CTL), which are crucial in cancer immunotherapy. Here, we...